The advancements made in drug development over the last decade have seen the arrival of a number of treatments that offer one-time cures and more effective therapies for conditions in small
New payment models, dedicated investment, and better health technology assessment are among a raft of changes needed to bring regenerative medicines to patients in Europe, according to a ne
The trial of Sangamo’s gene-editing treatment for a rare and debilitating disease has got off to a good start, with no safety concerns reported so far.
Europe’s regulator is looking for ways to stimulate the development of advanced therapies, after only a handful of such products reached the market in eight years since the introduction of
As the ASCO congress drew to a close, Johnson & Johnson filed for FDA approval of its BCMA-targeting CAR-T therapy Carvykti for use earlier in the treatment pathway fo
Health systems globally have reached a critical inflexion point, where ageing populations and tightening budgets mean we can no longer continue to purely treat late-stage symptomatic diseas